ClinicalTrials.gg
CompletedNCT05159895Updated May 25, 2022

Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects

A Phase 1 interventional study of [14C]-DZD9008 in Healthy Volunteers, sponsored by Dizal Pharmaceuticals. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-25.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

This is a phase 1, open-label, ADME study with single oral administration of [14C]-DZD9008 in healthy subjects.

Read the detailed description

Phase 1 study to evaluate the excretion of DZD9008 radioactive dose, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C]-DZD9008 in healthy male subjects. The purpose of this study is to investigate ADME properties of DZD9008 by analyzing blood, urine and feces samples collected during the study

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between 18 and 60 years of age, with of 18.0 to 30.0 kg/m2. Body weight: ≥55 kg,and ≤ 100 kg.
  • In good health, determined by no findings from medical history, physical examination, 12-lead , vital sign measurements, clinical laboratory evaluations.
  • Regular bowel movements (ie, average production of ≥ 1 or ≤ 3 bowel movements a day).
  • Adhere to specific requirements
  • ≥ 90 mL/min/1.73 m2.
  • and alanine aminotransferase must be ≤2.5 × (ULN) and total ≤1.5 × ULN.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI, neurological, respiratory, endocrine, or psychiatric disorder.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator, or history of hypersensitivity to DZD9008, its , or drugs with a similar chemical structure or class.
  • History of stomach or intestinal surgery history or presence of hepatic or renal disease or surgical procedure that would potentially alter absorption and/or excretion of orally-administered drugs (uncomplicated appendectomy and hernia repair will be allowed; cholecystectomy will not be allowed).
  • Any abnormalities in physical examination performed at check-in, vital signs (supine systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg, and pulse rate ≥100 or ≤35 beats per minute) or clinical laboratory evaluations as judged by the investigator (or designee).
  • Any clinically important abnormalities in rhythm, conduction, or morphology of resting 12-lead , interval >450 msec, as judged by the investigator (or designee).
  • A history of additional risk factors for Torsades de pointes (eg, heart failure, hypokalemia, family history of Long QT syndrome).
  • Positive/reactive results on screening tests for serum surface antigen, antibody, or (Appendix 2).
  • Acute illness, surgical procedures or trauma from within 2 weeks before screening until the first administration of the IMP.
  • Subjects with active or neoplastic disease in the previous 12 months.
  • Ongoing or planned inpatient surgery, dental procedure, or hospitalization during the study.
  • Administration of a coronavirus disease 2019 (COVID-19) vaccine in the past 30 days prior to dosing.
  • Use or intend to use any medications/products known to alter drug AME processes, including St. John's wort, within 30 days prior to check-in, unless deemed acceptable by the investigator (or designee).
  • Use or intend to use any prescription medications/products within 28 days prior to check-in, unless deemed acceptable by the investigator (or designee). Exceptions may be allowed on a case by case basis as agreed by the investigator and sponsor's medical monitor if considered not to interfere with the aims of the study.
  • Use or intend to use slow-release medications/products considered to still be active within 14 days prior to check-in, unless deemed acceptable by the investigator (or designee).
  • Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations, gastric pH modifiers, and neutralizing antacids within 7 days prior to check-in, unless deemed acceptable by the investigator (or designee).
  • Subjects will avoid the use of any prescription or nonprescription medications/products or herbal remedies that are strong/moderate inhibitors or inducers within 28 days prior to check-in through the end of study, unless deemed acceptable by the Investigator.
  • Subjects will avoid the use of any prescription or nonprescription medications/products or herbal remedies that are transporter (eg, P-gp) inhibitors or inducers within 28 days prior to the check-in through the end of study, unless deemed acceptable by the Investigator.
  • Subjects should avoid the use of proton pump inhibitors from 7 days prior to check-in through 5 days postdose. For H2-antagonists or antacids, administration will follow the staggered schedule per protocol.
  • Subjects who received a live or in the 2 weeks prior to IMP administration.
  • Participation in a clinical study involving administration of an drug (new chemical entity defined as a compound which has not been approved for marketing) or participation in any other clinical study (including methodology studies where no drugs were given) in the past 90 days prior to dosing.
  • Subjects who have participated in any radiolabeled drug studies in the last 12 months prior to check-in.
  • Have previously completed or withdrawn from this study or any other study investigating DZD9008 and have previously received DZD9008.
  • History of alcohol abuse or excessive alcohol consumption, defined as > 21 units per week for males. One unit of alcohol equals 8.5 oz (250 mL) beer, 0.85 oz (25 mL) liquor, or 2.4 oz (125 mL) wine.
  • Positive urine drug detected at screening, positive urinary alcohol test result or positive urine drug detected at check-in.
  • History or suspected history of alcoholism or drug/chemical abuse within 2 years prior to check-in, as judged by the investigator (or designee).
  • Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in.
  • Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages within 7 days prior to check-in.
  • Receipt of blood products within 2 months prior to check-in.
  • Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, from 6 weeks prior to screening, or any blood loss greater than 500 mL during the 3 months prior to screening.
  • Poor peripheral venous access.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]-DZD9008

    A Single dose of \[14C\]-DZD9008

    Drug: [14C]-DZD9008

Interventions

  • Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration

06

What researchers measure

Primary outcomes

  1. Percentage of Total Radioactivity (Cum% Dose) Recovered in Urine Relative to the Administered Radioactive Dose

    Time frame: Up to 85 days

  2. Percentage of Total Radioactivity (Cum% Dose) Recovered in Feces Relative to the Administered Radioactive Dose

    Time frame: Up to 85 days

  3. Amount of Total Radioactivity Excreted in Urine (Ae [UR])

    Time frame: Up to 85 days

  4. Amount of Total Radioactivity Excreted in Feces (Ae [Fe])

    Time frame: Up to 85 days

  5. Percentage of Administered Radioactive Dose (%Dose) Excreted in Urine for [14C]-DZD9008

    Time frame: Up to 85 days

  6. Percentage of Administered Radioactive Dose (%Dose) Excreted in Feces for [14C]-DZD9008

    Time frame: Up to 85 days

07

Study locations

1 site
  • Labcorp Clinical Research Unit, Madison site
    Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Mar 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Dec 16, 2021
StartActual
Sep 24, 2021
Primary completionActual
Mar 30, 2022
CompletionActual
Mar 30, 2022
Last update
May 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05159895
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Sep 24, 2021
Primary completion
Mar 30, 2022
Completion
Mar 30, 2022
Last update
May 25, 2022

Study contacts

Blanchard
principal investigator · Covance

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sunvozertinib

Start the discussion